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Abstract
Background: Allergic rhinitis is one of the most common health complaints worldwide. Complementary and alternative
medical approaches have been employed to relieve allergic rhinitis symptoms and to avoid the side effects of conventional
medication. Acupuncture has been widely used to treat patients with allergic rhinitis, but the available evidence of its
effectiveness is insufficient. Our objective is to evaluate the effectiveness of acupuncture in patients in Korea and China
with persistent allergic rhinitis compared to sham acupuncture treatment or waitlist control.
Methods: This study consists of a multi-centre (two centres in Korea and two centres in China), randomised, controlled
trial with three parallel arms (active acupuncture, sham acupuncture, and waitlist group). The active acupuncture and
sham acupuncture groups will receive real or sham acupuncture treatment, respectively, three times per week for a total
of 12 sessions over four weeks. Post-treatment follow-up will be performed a month later to complement these 12
acupuncture sessions. Participants in the waitlist group will not receive real or sham acupuncture treatments during this
period but will only be required to keep recording their symptoms in a daily diary. After four weeks, the same treatment
given to the active acupuncture group will be provided to the waitlist group.
Discussion: This trial will provide evidence for the effectiveness of acupuncture as a treatment for persistent allergic
rhinitis. The primary outcome between groups is a change in the self-reported total nasal symptom score (i.e., nasal
obstruction, rhinorrhea, sneezing, and itching) from baseline at the fourth week. Secondary outcome measures include
the Rhinitis Quality of Life Questionnaire score and total non-nasal symptom score (i.e., headache, itching, pain, eye-
dropping). The quantity of conventional relief medication used during the follow-up period is another secondary outcome
measure.
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Allergic rhinitis (AR) is a highly prevalent major chronic
respiratory disease. It significantly impacts quality of life
(QoL) and creates an economic burden. AR can be classi-
fied as intermittent or persistent allergic rhinitis (PER), as
described by the recent 'Allergic Rhinitis and its Impact on
Asthma (ARIA)' guidelines [1]. The conventional treat-
ment of AR symptoms, such as nasal obstruction, rhinor-
rhea, sneezing, and itching, includes the use of intranasal
corticosteroids, oral anti-histamines with or without
decongestants, immunotherapy, and education [2]. Sub-
stantial numbers of patients with AR are not satisfied with
conventional medical treatment and repeatedly experi-
ence side effects. As a result, a large number of patients
with AR are turning to complementary and alternative
treatments [3,4].
Acupuncture not only produces an anti-nociceptive effect,
but also has anti-inflammatory or immunomodulatory
effects against chronic inflammatory conditions in
humans [5]. The anti-inflammatory action of acupuncture
is thought to be mediated by neural immune reflexes
[6,7], i.e., the cholinergic anti-inflammatory pathway of
the central nervous system [8]. Although firm evidence
has not been established, acupuncture has been used by
patients with AR. The results of our systematic review of
six randomised controlled trials (RCTs) on acupuncture
for PER revealed that acupuncture had a favourable effect
on AR symptom scores compared to placebo acupuncture
(standardised mean difference: 0.45, 95% CI: 0.13 – 0.78)
[9]. However, the results of our review on the efficacy of
acupuncture in the treatment of AR were inconclusive,
consistent with other studies [10,11]. This may be because
all relevant RCTs were limited by methodological defects,
including inappropriate sample size, inappropriate pla-
cebo treatment, missing information, and lack of clarity
about the quality of the acupuncture practitioners [12,13].
A deficiency is evident even in a recent, high-quality ran-
domised controlled trial [14] in which acupuncture was
used for PER in an eight-week treatment and 12-week fol-
low-up period. The results showed an improvement in the
cumulative seven-day scores between the active and sham
acupuncture groups. In this study, Xue et al. used a shorter
needle in the placebo procedure compared to the active
acupuncture group. This suggests that their strategy may
be flawed with respect to patient blinding. Furthermore,
most RCTs for AR allowed the concomitant use of phar-
macological medication for symptomatic relief of AR, or
acupuncture was compared to conventional medication
and not to placebo needle treatment. Success of the blind-
ing procedure has not been assessed in RCTs, apart from
one trial [15]. Consequently, the difference in outcomes
between the two groups could be unrelated to the effect of
acupuncture itself, and may be influenced by the use of
over-the-counter (OTC) or conventional medications that
yield symptomatic relief. Thus, disallowance of concomi-
tant medications is needed in a randomised controlled
trial for PER in order to detect the specific effects of acu-
puncture.
With these constraints, we planned a rigorous multi-cen-
tre randomised controlled trial with a large sample size.
Method/design
Objective
The aim of this study is to investigate the effectiveness of
acupuncture compared with sham acupuncture or waitlist
in patients with moderate to severe PER in Korea and
China.
Primary outcome
Primary outcome will be the change in the weekly average
of total nasal symptom score (TNSS) recorded in partici-
pants' diaries between the one-week of run-in period and
the 4Pth week of the study. This scoring system was previ-
ously validated [14,16].
Secondary outcomes
Secondary outcome measures include the Rhinitis Quality
of Life Questionnaire (RQLQ) [17] score and a total non-
nasal symptom score (i.e., headache, itching, pain, eye-
dropping) [14] after the 12-session/four-week acupunc-
ture treatment period. The quantity of conventional relief
medication used during follow-up period (four weeks)
will also be recorded.
Design
A multi-centre (two centres in Korea and two in China),
randomised, subject- and assessor-blinded, sham acu-
puncture controlled trial will be conducted at the Depart-
ment of Acupuncture and Moxibustion, Kyung-Hee
University Medical Centre in Seoul, the Acupuncture and
Moxibustion Research Centre of the Korean Institute of
Oriental Medicine (KIOM) in Daejeon, the Acupuncture
and Moxibustion Clinic of Guang'anmen Hospital, and
Dongzhimen Hospital at Beijing. The study will be
sequentially conducted as follows: a run-in period of one
week prior to randomisation, a treatment period of four
weeks (three sessions per week), and a follow-up period of
four weeks. The total study period will be nine weeks. At
the end of the run-in period, participants will be ran-
domised to the active acupuncture group, the sham acu-
puncture group, or the waitlist group by a computer-
generated random number list (Figure 1).
Eligibility
Inclusion criteria
Eligible participants will be those previously diagnosed
with moderate to severe PER, according to the ARIA crite-
ria. Patients will be required to complete the baseline ARPage 2 of 8
(page number not for citation purposes)
Trials 2009, 10:54 http://www.trialsjournal.com/content/10/1/54diary. Written informed consent will be obtained from
each participant. Participants ≥ 18 years of age will be
recruited from each centre via local newspaper advertise-
ments and posted notices. Since the research involves
moderate to severe PER or severe PER [1], the inclusion
criteria will include greater than four days/week and
greater than four consecutive weeks of symptoms and one
or more of the following conditions: sleep disturbance,
impairment of daily activities such as sports and/or lei-
sure, impairment of school or work, or troublesome
symptoms. All participants will have to show at least one
positive result on an allergic skin prick reaction test. A
standard panel of antigens will be used, i.e., positive (his-
tamine) and negative (saline) controls, Dermatophagoides
farinae, Dermatophagoides pteronyssinus, dog fur, cat fur,
short ragweed, Orchard grass, Bermuda grass, Mugwort,
Hazel, Alternaria tenuis, Aspergillus fumigatus, Candida
albicans, Cladosporium herbarum, Alder, Beech, and cock-
roach (Blatella germanica) (Allergopharma, Germany).
Participants will be instructed to stop PER symptomatic
relief medication during the run-in and treatment periods
and will be provided the usual care instruction for AR.
During the follow-up period, they will be allowed to start
relief medication, if required.
Study Flow ChartFigure 1
Study Flow Chart.
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Participants will be excluded if they suffer from serious
medical conditions, such as uncontrolled hypertension,
diabetes mellitus requiring insulin injection, past or cur-
rent malignant tumour, severe dyslipidaemia, liver or kid-
ney dysfunction, anaemia, active pulmonary tuberculosis,
or other infectious or systemic diseases inappropriate for
treatment with acupuncture.
Participants will not be eligible if they have congenital
nasal abnormalities, sinusitis, active asthma, a history of
nose surgery, received systemically administered corticos-
teroids within six months prior to enrolment, or received
alternative and complementary treatment, (i.e., acupunc-
ture or herbal medication) for AR within the previous six
months. Typical oral and nasal H1 blockers, intranasal/
oral corticosteroids, or nasal anti-cholinergic medication
will be stopped at least one week before enrolment. OTC
drugs will be allowed for managing episodic colds, head-
aches, dyspepsia, etc. However, participants will be asked
to disclose all medication use prior to enrolment. OTC
drugs containing an H1 anti-histamine or anti-cholinergic
component will not be allowed, since they may directly
affect nasal symptoms. We will record the drugs taken by
each participant at every visit, and participants will be
requested to notify us of any change to their medication/
supplement regimen. Additional acupuncture treatments,
herbal prescriptions, or therapeutic intervention by other
clinicians will not be allowed during the treatment period.
Participants in the waitlist group will not receive acupunc-
ture or sham acupuncture treatments during the study.
After four weeks, if participants elect to try the acupunc-
ture treatment, the real acupuncture treatment will be pro-
vided.
Acupuncture treatment protocol
Acupuncture intervention and sham acupuncture
Acupuncture will be performed by certified acupuncture
medical doctors at four centres. Qualified specialists of
acupuncture in traditional Korean or Chinese medicine
with at least three years of clinical experience will perform
the acupuncture in this study. All treatment regimens will
be standardised between Korean and Chinese practition-
ers via video and international workshops. Participants
will be randomly assigned to the active acupuncture
group, the sham acupuncture group, or the waitlist group.
The active acupuncture and sham acupuncture group par-
ticipants will receive real and sham acupuncture treat-
ments respectively, three times/week for a total of 12
sessions over four weeks. A 0.20 mm (diameter) × 30 mm
(length) disposable needle (Dongbang Acupuncture Inc,
Korea) will be used. For the active acupuncture group, 10
acupuncture points (bilateral LI4, LI20, ST2, and ST36,
unilateral EX-1 and GV23) according to 'WHO Standard
Acupuncture Point Location' [18] were selected for use
based on an expert discussion held in Beijing in Decem-
ber, 2008. These acupuncture points were selected accord-
ing to traditional Chinese medicine (TCM) theory, which
is quite different from that of conventional medicine.
Briefly, the basic therapeutic strategies of acupuncture,
based on a meridian system, is to correct the body's core
imbalances in order to disperse blocked Qi and blood in
treating disease [19]. According to the TCM theory, when
an acupuncture point is stimulated, treatment effects tend
to occur in specific parts of the body along the meridian
that contains this specific acupuncture point. There are
two categories of acupuncture points used to effectively
regulate Qi and blood for syndromes: local points and dis-
tal points. In establishing an acupuncture strategy for this
study, we focused on the imbalance of the Large Intestine
and/or Stomach meridian and/or Governor Vessel due to
an invasion of pathogenic agents, such as cold, wind, and
damp, as the key pathogenesis of PER. These three key
meridians associated with PER flow together through the
nose, and are therefore closely connected with respiratory
function. In order to disperse pathologic Qi and blood
from these meridians and improve the function of the
nose and sinuses, the local or adjacent points, including
LI20 in the Large intestine meridian, ST2 in the Stomach
meridian, GV23 in the Governor vessel and EX1, were
selected. The remote points, including LI4 and ST36, were
selected to correct the imbalance of the relevant meridians
and organs. LI4 was selected for lung Qi deficiency syn-
drome, and ST36 for spleen Qi deficiency syndrome.
These two syndromes represent the pathologic basis of
PER in TCM theory.
As for treatment sessions, previous high quality trials
[14,16] used a total of 16 acupuncture sessions, twice a
week for eight weeks. But those trials allowed the concom-
itant use of conventional medication for symptomatic
relief of AR, so interpretation of the efficacy of acupunc-
ture is limited. In contrast to those studies, we added one
additional session of acupuncture treatment per week
(i.e., three times/week) without allowing PER symptom
relievers; this addition was thought to compensate for the
reduced effect of not using conventional medication. As
with treatment duration, we considered four weeks to be
a sufficient period of time to obtain clinically relevant
improvement based on clinical experiences with PER
patients. The needles will be inserted to a depth of 7–30
mm, depending on the points selected. In order to achieve
de-qi sensation for real acupuncture treatment, the needles
will be manually manipulated and maintained for 20
minutes, with manual stimulations at the start and just
before the withdrawal of needles. Additional interven-
tions, such as infrared irradiation or electronic stimula-
tion, will not be allowed during acupuncture treatment.
For real acupuncture treatment, needles will be inserted
into the aforementioned acupuncture points at an appro-Page 4 of 8
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ple, at EX1, the needle will be inserted to a depth of 20 to
30 mm in an oblique direction towards the nose with
respect to the skin. Each needle will be rotated until the
participant and doctor feel de-qi sensations. For the sham
acupuncture treatment, the needles (the same type used
for the active acupuncture treatment) will be inserted at
non-acupuncture point sites, 1 – 1.5 cm from the acu-
puncture points. However, they will be inserted to a depth
of 3 – 5 mm perpendicularly to the skin, using a hollow
pool and a shallow needling technique to avoid de-qi. The
needle will then be rotated once in order to preserve
patient blinding. The duration of this procedure will be
the same as the real acupuncture treatment.
Needle sites in both active and sham acupuncture groups
will be swabbed with 2% boric acid before insertion. On
withdrawal of the needle, dry sterilised cotton balls will be
firmly applied to the insertion points. Blood pressure will
be measured before and after acupuncture treatment.
Before acupuncture, each participant will be evaluated by
an assessor blinded to participants' random allocation,
and their symptoms and total non-nasal symptom scores
will be recorded. The level of any discomfort in the acu-
puncture or sham acupuncture will also be monitored.
Outcome measures
After screening, participants who satisfied the entry
requirements will begin the run-in period. During this
period, participants will document the four nasal symp-
toms on a diary card once per day. These scores for nasal
obstruction, rhinorrhea, sneezing, and itching will be
summed to yield the TNSS. Each symptom is graded on a
five-point scale (0 = no symptom; 1 = mild; 2 = moderate;
3 = severe; 4 = very severe). Weekly averages of TNSS will
be calculated and compared among groups throughout
the study period. In addition, TNSS will be reviewed by an
assessor blinded to the participants' treatment group at
each visit. At the end of the run-in period, the RQLQ
scores will be examined in the Korean and Mandarin Chi-
nese versions of the questionnaire [20]. RQLQ measures
the influence of AR on QoL and consists of 28 items in
seven domains: sleep, non-hay fever symptoms, practical
problems, nose symptoms, eye symptoms, activity, and
emotional function in everyday life, all based on a sum
score (range: 0 – 6). The RQLQ score will be blindly
assessed three times: baseline, at the end of treatment, and
at the end of the follow-up period. Participants in the
active acupuncture group and sham acupuncture group
will record their use of PER relief medications daily during
the follow-up period.
We will estimate the expectation of participants using the
credibility and expectancy questionnaire to determine
whether expectations affected outcomes [21]. Blinding
will be assessed by asking participants what arm they
thought they were in (active or sham acupuncture group,
or "don't know") at the end of trial, and why they believed




Analysis will be performed for each of the following
groups: 1) an intention-to-treat population consisting of
all randomised participants with at least one measurable
outcome report following acupuncture treatment (any
missing data will be replaced with the last observation val-
Table 1: Acupuncture points and needling procedure for real and sham acupuncture.
Real Point Angle and Direction Depth
(mm)
Sham point
LI20 (Both) Obliquely along the nasolabial sulcus towards the root of nose 
with respect to the skin
20–30 Lateral 1.5 cm and Downward 1 cm to LI20.
ST2 (Both) Transversely, upward to the centre of the pupil with respect to 
the skin
7–10 Lateral 1.5 cm to ST2
EX1 (unilateral) Transversely, downward to the nose 20–30 Upward 1.5 cm, Rt. Lateral 1 cm to EX1
GV23 (unilateral) Transversely, downward to the forehead with respect to the 
skin
20–30 Rt. Lateral 1 cm to GV23
LI4 (Both) Perpendicular to the skin 20–30 Posterior to the web margin between the first and 
second phalanges
ST36 (Both) Perpendicular to the skin 20–30 Medial 1.5 cm to ST36
In the sham acupuncture procedure, the needle will be inserted at each sham point to a depth of 3–5 mm, perpendicular to the skin, using a needle 
tube with a one-time rotationPage 5 of 8
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ticipants without major protocol deviations. All data will
be analysed descriptively. All main analyses will be based
on the intention-to-treat population. For primary and sec-
ondary outcome measures, analysis of covariance
(ANCOVA) using the differences in the change of out-
come variable scores as the dependent variable, baseline
outcome variable scores as the covariate, and allocated
group and centres as the fixed factors will be performed.
To compare the active acupuncture group with the sham
acupuncture group and with the waitlist group, a single
ANCOVA using dummy variables for the sham and wait-
list group (thus coded 0, 0; 1, 0; 0, 1 for the active acu-
puncture group, sham acupuncture group, and waitlist
group, respectively) will be conducted. All adverse events
reported during the study will be included in the case
report forms; the incidence of adverse events will be calcu-
lated. The percentage of subjects with adverse events in
each group will be calculated and compared using the chi-
squared test or Fisher's exact test.
Statistical analyses will be performed using the SAS statis-
tical package program (ver. 9.1.3, SAS Institute Inc, Cary,
NC), and the level of significance will be established at α
= 0.05.
Sample size
For power analysis and sample size calculation, we con-
ducted a pilot study with a sample size of 19 (9 in the
active acupuncture arm and 10 in the sham acupuncture
group). In this study, the pooled SD of TNSS was 4.74 and
the mean difference of TNSS change between the active
and sham acupuncture group was 2.53. This difference
was larger than that of recent successful acupuncture RCT
on PER, reported as 1.8 [14]. TNSS reduction in the active
acupuncture group in our pilot study was 4.12, higher
than the minimal clinically important differences (i.e.
2.2) [22]. Therefore, the result of our pilot study showed
the potential of acupuncture treatment and supported the
need for the present trial. The SD of the pilot study was
adjusted for better application to the true population. In
order to achieve this adjustment, we multiplied the SD
from the pilot data by a correction factor of 1.148. This
adjustment provides a 75% probability that the resulting
estimate of SD will be at least as large as the true popula-
tion SD [23]. For the sample size calculation, we estab-
lished a sample size (N) for an independent t test using
the adjusted SD, and the difference in TNSS change
between the active and sham acupuncture group with a
power of 80% and alpha value of 2.5% (two-tailed). We
then estimated a Pearson correlation value (R) of 0.76
between baseline and the change of TNSS in our pilot
study. Finally, we multiplied N by (1-R2) to yield the sam-
ple size needed for ANCOVA analysis [24]. The results
indicated that the number of subjects in the active acu-
puncture group and in the sham acupuncture group was
38. If we compare the change in TNSS for the active acu-
puncture group with that of the waitlist group, assuming
that pooled SD and R are similar to our pilot study, the
differences between groups will be larger, and thus 38
subjects in the waitlist group size will be enough to detect
significant differences in the change in TNSS for the active
acupuncture group. We applied a 2:2:1 ratio to the active
acupuncture group, sham acupuncture group, and waitlist
group, respectively, and we expect that this allocation
ratio will raise the statistical power. We plan to enrol 95,
95, and 48 participants in the active acupuncture group,
sham acupuncture group, and waitlisted group, respec-
tively, allowing for a 20% withdrawal rate.
Data handling
Investigators will enter the collected data into case report
forms; unclear or out of range entries and omissions will
be recorded on data query forms, which will be returned
to the investigational site for resolution. The data from all
centres will be pooled and summarised according to
demographic baseline characteristics, effectiveness, and
safety observations.
Data and safety monitoring
Regular monitoring will be conducted for quality control.
Investigators will also convene regularly to discuss practi-
cal issues that may be encountered, such as adjusting the
recruitment capacity within each centre, dealing with seri-
ous adverse events, revising the protocol, as well as any
other important issues raised by the investigators or par-
ticipants. The assessment of safety will be based mainly on
the frequency of adverse events, as well as particularly seri-
ous adverse events. Information regarding adverse events
will be summarised by presenting the number and per-
centage of participants that experienced adverse events,
with the information also categorized according to the
body region affected. Any other collected information
(e.g., severity or relevance to acupuncture treatments) will
be included in the data and safety monitoring reports.
Randomisation and allocation
Randomisation will be performed by researchers who are
not in direct contact with the participants. Participants
and assessors will be blinded to the treatment allocation.
The acupuncture practitioners cannot be blinded due to
the nature of the intervention, but they will not be permit-
ted to communicate with the participants or assessors
regarding treatment procedures and responses.
Ultimately, 238 participants will be randomised into the
three groups at four centres. The number of subjects
planned for each location will be: clinical research centre
of KIOM – 70, Kyung-Hee hospital – 68, Dongzhimen
hospital – 50, Guang'anmen hospital – 50. RandomPage 6 of 8
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ried out by a computer statistics software package (Ver-
sion 9.1.3; SAS Institute Inc, Cary, NC) for the central
control. The ratio of random allocation for the acupunc-
ture group, sham acupuncture group, and waitlist group
will be 2, 2, and 1, respectively, within each centre. The
exact block size will be concealed from personnel who
will contact participants directly. Separate randomisation
tables will be delivered to each centre. Tables will be con-
cealed from anyone involved in the study except for per-
sonnel involved in the random assignment.
Just before randomisation, participants will be informed
that they will be assigned to one of three groups, includ-
ing two that have the potential to reduce PER symptoms
and a waitlist for treatment. We will not inform the partic-
ipants in the active and sham groups about which treat-
ment they receive until the end of the study. To eliminate
observation bias, assessors will be blinded prior to analy-
sis of the data.
A sealed numbered envelope for each participant will be
given to researchers involved in random allocation, to be
opened at each participant's randomisation visit (Visit 2).
The serial numbers of sealed and open envelopes and
their matching registered participants will be checked and
recorded in logs just before and immediately after open-
ing each envelope by independent personnel not in
charge of opening envelopes. Any error or inappropriate-
ness with random allocation in each centre will be
reported to the central coordination centre (KIOM)
immediately, and a new randomisation table will be gen-
erated beginning from the problematic serial number and
applied to the participants thereafter.
Ethics
Written consent will be obtained from each participant.
This study was approved by all relevant local ethics review
boards: Kyung-Hee University Medical Centre, Daejeon
Oriental Hospital in Korea and Dongzhimen hospital in
China.
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